BMS 303141 Struktur

BMS 303141

Bezeichnung:BMS 303141

CAS-Nr943962-47-8

Englisch Name:BMS 303141

CBNumberCB32627606

SummenformelC19H15Cl2NO4S

Molgewicht424.3

MOL-Datei943962-47-8.mol

BMS 303141 physikalisch-chemischer Eigenschaften

Siedepunkt	591.5±60.0 °C(Predicted)
Dichte	1.462±0.06 g/cm3(Predicted)
storage temp.	2-8°C
Löslichkeit	DMSO: soluble20mg/mL, clear
pka	4.94±0.48(Predicted)
Aggregatzustand	powder
Farbe	white to beige
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

Sicherheit

WGK Germany

Gefahreninformationscode (GHS)

BMS 303141 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
BMS-303141 (943963-47-8) is a potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 μM. Inhibits lipid biosynthesis, IC50=8 μM in HepG2 cells.1,2?Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2?A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2?Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3?Reduces cell cycle progression in iBN cells.4
Verwenden
BMS-303141 has been used for inhibition of ATP citrate lyase in breast cancer cell lines.
Definition
ChEBI: 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide is a member of biphenyls.
Biochem/physiol Actions
BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model.
Lager
Store at -20°C
Einzelnachweise
1) Li?et al. (2007),?2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors; Bioorg. Med. Chem.,?17?3208 2) Ma?et al.?(2009),?A novel direct homogeneous assay for ATP citrate lyase; J. Lipid Res.,?50?2131 3) Shah?et al.?(2016),?Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism; Oncotarget,?7?43713 4) Rhee and Dekoter (2017),?Regulation of Lipid Metabolism and Cell Cycle Progression by PU.1 in Myeloid Progenitor Cells; Blood,?130?2433

BMS 303141 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

943962-47-8, BMS 303141 Verwandte Suche:

Send Inquriy